943 results match your criteria Blood Cancer Journal [Journal]


Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL.

Blood Cancer J 2020 May 26;10(5):61. Epub 2020 May 26.

The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Mutations of ABL1 are the dominant mechanism of relapse in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL). We performed highly accurate Duplex Sequencing of exons 4-10 of ABL1 on bone marrow or peripheral blood samples from 63 adult patients with previously untreated Ph + ALL who received induction with intensive chemotherapy plus a BCR-ABL1 TKI. We identified ABL1 mutations prior to BCR-ABL1 TKI exposure in 78% of patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-020-0329-yDOI Listing

Combining gene expression profiling and machine learning to diagnose B-cell non-Hodgkin lymphoma.

Blood Cancer J 2020 May 22;10(5):59. Epub 2020 May 22.

INSERM U1245, Centre Henri Becquerel, UNIROUEN, University of Normandie, Rouen, France.

Non-Hodgkin B-cell lymphomas (B-NHLs) are a highly heterogeneous group of mature B-cell malignancies. Their classification thus requires skillful evaluation by expert hematopathologists, but the risk of error remains higher in these tumors than in many other areas of pathology. To facilitate diagnosis, we have thus developed a gene expression assay able to discriminate the seven most frequent B-cell NHL categories. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-020-0322-5DOI Listing

Staphylococcus aureus enterotoxins induce FOXP3 in neoplastic T cells in Sézary syndrome.

Blood Cancer J 2020 May 14;10(5):57. Epub 2020 May 14.

Department of Immunology and Microbiology; LEO Foundation Skin Immunology Research Center, University of Copenhagen, Copenhagen, Denmark.

Sézary syndrome (SS) is a heterogeneous leukemic subtype of cutaneous T-cell lymphoma (CTCL) with generalized erythroderma, lymphadenopathy, and a poor prognosis. Advanced disease is invariably associated with severe immune dysregulation and the majority of patients die from infectious complications caused by microorganisms such as, Staphylococcus aureus, rather than from the lymphoma per se. Here, we examined if staphylococcal enterotoxins (SE) may shape the phenotype of malignant SS cells, including expression of the regulatory T-cell-associated marker FOXP3. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-020-0324-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225173PMC

Changes in long term survival after diagnosis with common hematologic malignancies in the early 21st century.

Blood Cancer J 2020 May 13;10(5):56. Epub 2020 May 13.

Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Five-year survival has increased for many hematologic malignancies in the 21st century. However, whether this has translated into greater long-term survival is unknown. Here, we examine 10- and 20-year survival for patients with multiple myeloma (MM), acute lymphoblastic leukemia (ALL), acute myeloblastic leukemia (AML), chronic lymphoid leukemia (CLL), chronic myeloid leukemia (CML), non-Hodgkin lymphoma (NHL), and Hodgkin lymphoma (HL). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-020-0323-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7221083PMC

Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT).

Blood Cancer J 2020 May 11;10(5):53. Epub 2020 May 11.

Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

SWOG S0777, a randomized phase III trial, compared bortezomib, lenalidomide and dexamethasone (VRd) with lenalidomide and dexamethasone (Rd). This updated analysis includes 460 patients evaluable for survival endpoints: 225 eligible and analyzable patients were randomized to Rd and 235 to VRd. The 6-month induction was six 28-day cycles of Rd and eight 21-day cycles of VRd followed by Rd maintenance for all patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-020-0311-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214419PMC

"Direct to Drug" screening as a precision medicine tool in multiple myeloma.

Blood Cancer J 2020 May 11;10(5):54. Epub 2020 May 11.

Department of Hematology/Oncology, Mayo Clinic, Scottsdale, AZ, USA.

Seventy-six FDA-approved oncology drugs and emerging therapeutics were evaluated in 25 multiple myeloma (MM) and 15 non-Hodgkin's lymphoma cell lines and in 113 primary MM samples. Ex vivo drug sensitivities were mined for associations with clinical phenotype, cytogenetic, genetic mutation, and transcriptional profiles. In primary MM samples, proteasome inhibitors, dinaciclib, selinexor, venetoclax, auranofin, and histone deacetylating agents had the broadest cytotoxicity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-020-0320-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214452PMC

The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?

Blood Cancer J 2020 May 6;10(5):52. Epub 2020 May 6.

Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.

We conducted a retrospective review of multiple myeloma (MM), smoldering multiple myeloma (SMM), and monoclonal gammopathy of undetermined significance (MGUS) patients seen at Mayo Clinic to determine whether a bone marrow biopsy (BM) is necessary in all patients diagnosed with a monoclonal protein. A total of 2254 MM, 397 SMM, and 5836 MGUS patients were included in the study. A total of 29 (1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-020-0319-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7203099PMC
May 2020
2.884 Impact Factor

Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia.

Blood Cancer J 2020 May 4;10(5):48. Epub 2020 May 4.

Department of leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

FLT3-ITD mutations in newly diagnosed acute myeloid leukemia (AML) are associated with worse overall survival (OS). FLT3-ITD diversity can further influence clinical outcomes. Addition of FLT3 inhibitors to standard chemotherapy has improved OS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-020-0318-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7198530PMC

Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up.

Blood Cancer J 2020 May 4;10(5):49. Epub 2020 May 4.

Duke University Medical Center, Division of Hematopathology and Department of Pathology, Durham, NC, USA.

Primary mediastinal large B-cell lymphoma (PMBCL) is a rare and distinct subtype of diffuse large B-cell lymphoma (DLBCL) without prognostic factors or a single standard of treatment clearly defined. In this study we performed retrospective analysis for clinical outcomes of 166 patients with PMBCL. In overall PMBCL, higher International Prognostic Index, stage, Ki-67 proliferation index, and positron emission tomography (PET) maximum standardized uptake values (SUVmax) at diagnosis were significantly associated with poorer survival, whereas MUM1 expression and higher peripheral blood lymphocyte/monocyte ratios were significantly associated with better survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-020-0312-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7198569PMC

Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype.

Blood Cancer J 2020 May 4;10(5):47. Epub 2020 May 4.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.

Normal karyotype in therapy-related acute myeloid leukemia (t-AML) is rare and the relative contribution of prior exposure to chemotherapy or radiotherapy to outcomes in these patients remains uncertain. We performed a retrospective study of 742 patients with newly diagnosed AML and normal karyotype (t-AML, n = 61, and non-t-AML, n = 681). Patients with t-AML were older but had a similar mutational profile compared to those with non-t-AML. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-020-0316-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7198507PMC
May 2020
2.884 Impact Factor

Impact of mitochondrial DNA mutations in multiple myeloma.

Blood Cancer J 2020 May 1;10(5):46. Epub 2020 May 1.

Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-020-0315-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7195394PMC

Dissecting racial disparities in multiple myeloma-clues from differential immunoglobulin levels.

Blood Cancer J 2020 Apr 28;10(4):44. Epub 2020 Apr 28.

Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK, B15 2TT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-020-0314-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188885PMC

DNA methylation and copy number variation profiling of T-cell lymphoblastic leukemia and lymphoma.

Blood Cancer J 2020 Apr 28;10(4):45. Epub 2020 Apr 28.

Department of Medical Biosciences, Umeå University, Umeå, Sweden.

Despite having common overlapping immunophenotypic and morphological features, T-cell lymphoblastic leukemia (T-ALL) and lymphoma (T-LBL) have distinct clinical manifestations, which may represent separate diseases. We investigated and compared the epigenetic and genetic landscape of adult and pediatric T-ALL (n = 77) and T-LBL (n = 15) patient samples by high-resolution genome-wide DNA methylation and Copy Number Variation (CNV) BeadChip arrays. DNA methylation profiling identified the presence of CpG island methylator phenotype (CIMP) subgroups within both pediatric and adult T-LBL and T-ALL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-020-0310-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188684PMC

DuoHexaBody-CD37, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies.

Blood Cancer J 2020 Apr 28;10(3):30. Epub 2020 Apr 28.

Genmab, Utrecht, The Netherlands.

Tetraspanin CD37 has recently received renewed interest as a therapeutic target for B-cell malignancies. Although complement-dependent cytotoxicity (CDC) is a powerful Fc-mediated effector function for killing hematological cancer cells, CD37-specific antibodies are generally poor inducers of CDC. To enhance CDC, the E430G mutation was introduced into humanized CD37 monoclonal IgG1 antibodies to drive more efficient IgG hexamer formation through intermolecular Fc-Fc interactions after cell surface antigen binding. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-020-0292-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186228PMC

A novel targeted RNA-Seq panel identifies a subset of adult patients with acute lymphoblastic leukemia with BCR-ABL1-like characteristics.

Blood Cancer J 2020 Apr 24;10(4):43. Epub 2020 Apr 24.

Hematology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.

BCR-ABL1-like B-cell precursor acute lymphoblastic leukemia (BCP-ALL) remains poorly characterized in adults. We sought to establish the frequency and outcome of adolescent and adult BCR-ABL1-like ALL using a novel RNA-Seq signature in a series of patients with BCP-ALL. To this end, we developed and tested an RNA-Seq custom panel of 42 genes related to a BCR-ABL1-like signature in a cohort of 100 patients with BCP-ALL and treated with risk-adapted ALL trials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-020-0308-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7182567PMC

A high definition picture of somatic mutations in chronic lymphoproliferative disorder of natural killer cells.

Blood Cancer J 2020 Apr 22;10(4):42. Epub 2020 Apr 22.

Department of Molecular Medicine, University of Padova, Padova, Italy.

The molecular pathogenesis of chronic lymphoproliferative disorder of natural killer (NK) cells (CLPD-NK) is poorly understood. Following the screening of 57 CLPD-NK patients, only five presented STAT3 mutations. WES profiling of 13 cases negative for STAT3/STAT5B mutations uncovered an average of 18 clonal, population rare and deleterious somatic variants per patient. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-020-0309-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7176632PMC

A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis.

Blood Cancer J 2020 Apr 14;10(4):41. Epub 2020 Apr 14.

Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.

Newly diagnosed AL amyloidosis patients were evaluated to develop a model for early assessment of treatment benefit at 6 months, integrating both hematologic (HR) and organ response (OR) assessment (testing cohort, Mayo: n = 473; validation cohort, Pavia: n = 575). Multiple OR were assessed as follows: All OR (AOR): response in all organs, mixed OR (MOR): response in some organs, no OR (NOR)]. AOR rates at 6 months improved with deepening HR; complete response (CR; 38%, 35%), very good partial response (VGPR; 30%, 26%), and partial response (PR; 16%, 21%), respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-020-0306-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156647PMC

A liquid biopsy to detect multidrug resistance and disease burden in multiple myeloma.

Blood Cancer J 2020 03 13;10(3):37. Epub 2020 Mar 13.

Graduate School of Health, Discipline of Pharmacy, University of Technology Sydney, Ultimo, NSW, 2007, Australia.

Multiple myeloma is an incurable cancer of bone marrow plasma cells, with a 5-year survival rate of 43%. Its incidence has increased by 126% since 1990. Treatment typically involves high-dose combination chemotherapy, but therapeutic response and patient survival are unpredictable and highly variable-attributed largely to the development of multidrug resistance (MDR). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-020-0304-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7070076PMC

Nfkbie-deficiency leads to increased susceptibility to develop B-cell lymphoproliferative disorders in aged mice.

Blood Cancer J 2020 03 13;10(3):38. Epub 2020 Mar 13.

INSERM U1170; équipe labélisée Ligue Nationale Contre le Cancer; Gustave Roussy, Villejuif, France.

Aberrant NF-κB activation is a hallmark of most B-cell malignancies. Recurrent inactivating somatic mutations in the NFKBIE gene, which encodes IκBε, an inhibitor of NF-κB-inducible activity, are reported in several B-cell malignancies with highest frequencies in chronic lymphocytic leukemia and primary mediastinal B-cell lymphoma, and account for a fraction of NF-κB pathway activation. The impact of NFKBIE deficiency on B-cell development and function remains, however, largely unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-020-0305-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7070037PMC

Early post-transplantation factors predict survival outcomes in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis.

Blood Cancer J 2020 03 10;10(3):36. Epub 2020 Mar 10.

Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, USA.

Factors predicting allogeneic hematopoietic cell transplantation (HCT) outcomes in myelofibrosis in the early post-HCT period have not been defined thus far. We attempt to study such factors that can help identify patients at a higher risk of relapse or death. This retrospective study included 79 patients who underwent first HCT for myelofibrosis at three centers between 2005 and 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-020-0302-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7064504PMC

Prevalence of monoclonal gammopathy of undetermined significance in a large population with annual medical check-ups in China.

Blood Cancer J 2020 03 9;10(3):34. Epub 2020 Mar 9.

Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-020-0303-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7062721PMC

Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis.

Blood Cancer J 2020 03 6;10(3):33. Epub 2020 Mar 6.

Division of Hematology, Mayo Clinic, Rochester, MN, USA.

Bortezomib-based regimens are widely used as induction therapy for multiple myeloma (MM). Unlike lenalidomide, the role of bortezomib in consolidation and maintenance therapy for MM is less clear. We performed a meta-analysis to evaluate the impact of bortezomib-based consolidation and maintenance therapy on survival outcomes and adverse events. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-020-0298-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7060191PMC

Patterns of change in treatment, response, and outcome in patients with follicular lymphoma over the last four decades: a single-center experience.

Blood Cancer J 2020 03 5;10(3):31. Epub 2020 Mar 5.

Department of Hematology, Hospital Clínic, Barcelona, Spain.

Although the introduction of immunotherapy has improved outcomes for follicular lymphoma (FL) patients, histological transformation (HT) and early relapse still confer a poor prognosis. We sought to describe the patterns of change in treatment, response, and outcome of FL patients at our institution over the last four decades. Seven hundred and twenty-seven patients (389 F/338 M; median age, 57 years) consecutively diagnosed with grade 1-3a FL between 1980 and 2017, categorized into four decades according to the time of diagnosis, constituted the study population. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-020-0299-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7058022PMC

Veno-occlusive disease/sinusoidal obstruction syndrome in patients with prior gemtuzumab ozogamicin: literature analysis of survival after defibrotide treatment.

Blood Cancer J 2020 03 4;10(3):29. Epub 2020 Mar 4.

Department of Pediatric Hematology, Oncology and Stem Cell Transplantation, University of Regensburg, Regensburg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-020-0286-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7055222PMC

Serum free light chain level at diagnosis in myeloma cast nephropathy-a multicentre study.

Blood Cancer J 2020 03 3;10(3):28. Epub 2020 Mar 3.

Department of Renal Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.

Myeloma cast nephropathy (MCN) is a common cause of severe renal impairment in multiple myeloma (MM). The level of free light chain (FLC) that causes MCN varies substantially and there is uncertainty about the threshold level that should be used to inform clinical practice. In a multicentre cohort study of 103 patients with a diagnosis of MM and biopsy-confirmed MCN made between 2002-2014, we report prospectively measured levels of serum FLC at diagnosis obtained using a single nephelometric assay (Freelite®) and we explore the relationship between serum FLC level at diagnosis with renal outcome and patient survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-020-0295-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7054310PMC

Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia.

Blood Cancer J 2020 03 3;10(3):26. Epub 2020 Mar 3.

Department of Haematology, Saint Antoine Hospital, Université Pierre et Marie Curie, INSERM UMR 938, Paris, France.

Following chemotherapy, secondary acute myeloid leukemia (sAML), occurring after antecedent hematologic diseases, previous chemotherapy or radiation, has an inferior prognosis compared with de novo AML. To define the outcome of sAML in the context of allogeneic stem cell transplantation (alloSCT), a retrospective, registry-based comparison was performed, including 11,439 patients with de novo and 1325 with sAML. Among transplants in first complete remission (CR1) (n = 8,600), the 3-year cumulative incidence of relapse (RI) and non-relapse mortality (NRM) was 28. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-020-0296-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7054545PMC

Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma.

Blood Cancer J 2020 02 28;10(2):24. Epub 2020 Feb 28.

University Hospital Tübingen, Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Tübingen, Germany.

The B-cell maturation antigen (BCMA) is currently being evaluated as promising tumor-associated surface antigen for T-cell-based immunotherapy approaches, such as CAR T cells and bispecific antibodies, in multiple myeloma (MM). Cytotoxic T cells bearing BCMA-specific T-cell receptors might further allow targeting HLA-presented antigens derived from the intracellular domain of BCMA. By analyzing a mass spectrometry-acquired immunopeptidome dataset of primary MM samples and MM cell lines for BCMA-derived HLA ligands, we identified the naturally presented HLA-B*18-restricted ligand P(BCMA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-020-0288-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048774PMC
February 2020

Risk-adjusted therapy for pediatric non-T cell ALL improves outcomes for standard risk patients: results of JACLS ALL-02.

Blood Cancer J 2020 02 27;10(2):23. Epub 2020 Feb 27.

Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.

This study was a second multicenter trial on childhood ALL by the Japan Childhood Leukemia Study Group (JACLS) to improve outcomes in non-T ALL. Between April 2002 and March 2008, 1138 children with non-T ALL were enrolled in the JACLS ALL-02 trial. Patients were stratified into three groups using age, white blood cell count, unfavorable genetic abnormalities, and treatment response: standard risk (SR), high risk (HR), and extremely high risk (ER). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-020-0287-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7046744PMC
February 2020

The new WHO classification for essential thrombocythemia calls for revision of available evidences.

Blood Cancer J 2020 02 25;10(2):22. Epub 2020 Feb 25.

Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.

In the 2016 revised classification of myeloproliferative neoplasms pre-fibrotic primary myelofibrosis (pre-PMF) was recognized as a separate entity, distinct from essential thrombocythemia (ET). Owing that the majority of cases falling in the pre-PMF category were previously diagnosed as ET, one may question about the need to re-evaluate the results of epidemiologic, clinical, and molecular studies, and the results of clinical trials in the two entities. Based on a critical review of recently published studies, pre-PMF usually presents with a distinct clinical and hematological presentation and higher frequency of constitutional symptoms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-020-0290-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7042222PMC
February 2020

Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis.

Blood Cancer J 2020 02 25;10(2):20. Epub 2020 Feb 25.

Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, MN, USA.

In patients with immunoglobulin light-chain (AL) amyloidosis, depth of hematologic response correlates with both organ response and overall survival. Our group has demonstrated that screening with a matrix-assisted laser desorption/ionization-time-of-flight (TOF) mass spectrometry (MS) is a quick, sensitive, and accurate means to diagnose and monitor the serum of patients with plasma cell disorders. Microflow liquid chromatography coupled with electrospray ionization and quadrupole TOF MS adds further sensitivity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-020-0291-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7042300PMC
February 2020
2.884 Impact Factor

Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis.

Blood Cancer J 2020 02 25;10(2):21. Epub 2020 Feb 25.

FROM Research Foundation, Papa Giovanni XXIIII Hospital, Bergamo, Italy.

Pre-fibrotic myelofibrosis (pre-PMF) and essential thrombocythemia (ET) are characterized by similarly increased rate of thrombotic events, but no study specifically analyzed risk factors for thrombosis in pre-PMF. In a multicenter cohort of 382 pre-PMF patients collected in this study, the rate of arterial and venous thrombosis after diagnosis was 1.0 and 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-020-0289-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7042364PMC
February 2020

Dissecting racial disparities in multiple myeloma.

Blood Cancer J 2020 02 17;10(2):19. Epub 2020 Feb 17.

Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, 02215, USA.

Multiple myeloma (MM) is a fatal plasma cell dyscrasia with a median overall survival of 5 to 10 years. MM progresses from the more common but often subclinical precursor states of monoclonal gammopathy of undetermined significance (MGUS), and smoldering multiple myeloma (SMM) to overt MM. There are large racial disparities in all stages of the disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-020-0284-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026439PMC
February 2020

Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma.

Blood Cancer J 2020 02 13;10(2):17. Epub 2020 Feb 13.

Dana-Farber Cancer Institute, Boston, MA, USA.

The evolving paradigm of continuous therapy and maintenance treatment approaches in multiple myeloma (MM) offers prolonged disease control and improved outcomes compared to traditional fixed-duration approaches. Potential benefits of long-term strategies include sustained control of disease symptoms, as well as continued cytoreduction and clonal control, leading to unmeasurable residual disease and the possibility of transforming MM into a chronic or functionally curable condition. "Continuous therapy" commonly refers to administering a doublet or triplet regimen until disease progression, whereas maintenance approaches typically involve single-agent or doublet treatment following more intensive prior therapy with autologous stem cell transplant (ASCT) or doublet, triplet, or even quadruplet induction therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-020-0273-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7018731PMC
February 2020

The RUNX1-ETO target gene RASSF2 suppresses t(8;21) AML development and regulates Rac GTPase signaling.

Blood Cancer J 2020 02 6;10(2):16. Epub 2020 Feb 6.

Moores Cancer Center, University of California San Diego, La Jolla, CA, 92093, USA.

Large-scale chromosomal translocations are frequent oncogenic drivers in acute myeloid leukemia (AML). These translocations often occur in critical transcriptional/epigenetic regulators and contribute to malignant cell growth through alteration of normal gene expression. Despite this knowledge, the specific gene expression alterations that contribute to the development of leukemia remain incompletely understood. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-020-0282-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005177PMC
February 2020

Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients.

Blood Cancer J 2020 02 6;10(2):14. Epub 2020 Feb 6.

Hospital Universitario de Salamanca (HUSAL), IBSAL, IBMCC (USAL-CSIC), CIBERONC, Salamanca, Spain.

Multiple myeloma is a heterogeneous disease whose pathogenesis has not been completely elucidated. Although B-cell receptors play a crucial role in myeloma pathogenesis, the impact of clonal immunoglobulin heavy-chain features in the outcome has not been extensively explored. Here we present the characterization of complete heavy-chain gene rearrangements in 413 myeloma patients treated in Spanish trials, including 113 patients characterized by next-generation sequencing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-020-0283-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004993PMC
February 2020

Phase I/II study of carfilzomib, bendamustine, and dexamethasone (CBD) in patients with newly diagnosed multiple myeloma.

Blood Cancer J 2020 02 3;10(2):13. Epub 2020 Feb 3.

Division of Hematology/Oncology, Columbia University Irving Medical Center, 161 Fort Washington Ave, New York, NY, 10032, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-020-0278-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997347PMC
February 2020